• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, November 19, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Methodological Flaws in Basophil Activation Testing Linked to Recurrent Perioperative Anaphylaxis

by
November 19, 2026
in Health
Reading Time: 7 mins read
0
Methodological Flaws in Basophil Activation Testing Linked to Recurrent Perioperative Anaphylaxis

Methodological Flaws in Basophil Activation Testing Linked to Recurrent Perioperative Anaphylaxis

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A detailed clinical investigation published in JA Clinical Reports reveals how methodological variability in the basophil activation test can yield deceptive findings that directly jeopardize surgical patient safety. The report documents the clinical trajectory of a 74-year-old female patient who suffered recurrent perioperative anaphylaxis after initial in vitro testing failed to identify cefazolin as the true causative agent. The basophil activation test, widely abbreviated as BAT, serves as an in vitro flow cytometric assay used to support the identification of culprit agents in immediate hypersensitivity reactions without subjecting individuals to direct provocation risks. However, investigators observed that non-standardized procedural factors, including early sample timing, prolonged incubation intervals, and insufficient allergen concentrations, produced a false-negative result for the primary culprit drug while generating misleading low-level signals for uninvolved anesthetic agents. This failure of identification culminated in repeated re-exposure to the allergen during a subsequent surgical attempt, underscoring the urgent necessity of methodological standardization and rigorous analytical interpretation in clinical allergy evaluations.

The basophil activation test operates by exposing whole blood specimens to suspected pharmacological agents in vitro and quantifying cell surface activation markers, specifically CD63 or CD203c, using flow cytometric analysis. By measuring cellular degranulation and activation outside the body, the assay provides a minimally invasive diagnostic adjunct that eliminates the physical hazard of re-challenging sensitized patients with potentially fatal compounds. Beyond its favorable safety profile, the method offers considerable operational flexibility because whole blood assays can be processed by qualified laboratory personnel in facilities outfitted with standard flow cytometry instrumentation. This practical feature proves advantageous when hospital constraints or a lack of specialized allergy staff prevent bedside evaluations. Despite these logistical benefits, in vivo skin testing persists as the primary diagnostic gold standard for evaluating suspected perioperative hypersensitivity, exhibiting an established diagnostic sensitivity of approximately 70 percent compared to an estimated sensitivity of roughly 50 percent for the basophil activation test. Furthermore, testing protocols across clinical laboratories remain variable, frequently differing in reaction timing, drug dilutions, biochemical reagents, and analytical criteria for defining a positive response.

The clinical dilemma originated when a 74-year-old woman, measuring 146 centimeters in height and weighing 59 kilograms, was scheduled to undergo elective arthroscopic meniscal repair. Her medical history was notable for systemic hypertension, but she presented with no prior documented drug allergies and had unremarkable preoperative laboratory evaluations. During the initial surgical attempt at another medical center, general anesthesia was induced with 50 micrograms of fentanyl and 120 milligrams of propofol, followed by maintenance with 5 percent desflurane. A supraglottic airway device was positioned, and peripheral nerve blocks targeting the femoral and sciatic nerves were executed using 30 milliliters of 0.25 percent levobupivacaine. Immediately following anesthetic induction, intravenous infusion of 1 gram of cefazolin was initiated. Eleven minutes into the anesthetic procedure, precisely upon completion of the antibiotic infusion, the patient experienced catastrophic circulatory collapse. Her systolic blood pressure plummeted into the 50 mmHg range and rapidly became unmeasurable, while her heart rate accelerated into the range of 100 to 110 beats per minute.

The patient exhibited severe hemodynamic instability that proved entirely refractory to intravenous boluses of 35 milligrams of ephedrine and 0.3 milligrams of phenylephrine, prompting the surgical team to abort the planned operation. Following the removal of the supraglottic airway device and emergence from general anesthesia, the patient reported acute chest discomfort and severe dyspnea, accompanied by a decline in oxygen saturation to 85 percent. Systolic blood pressure continued to hover dangerously in the 50 to 60 mmHg range despite continuous infusion of dopamine at rates between 5 and 7 micrograms per kilogram per minute. Suspecting an acute cardiovascular event, clinicians coordinated an emergency transfer to a tertiary hospital. Approximately 90 minutes following anesthetic induction, the patient developed profound bradycardia with her heart rate decelerating to 30 beats per minute, necessitating resuscitation with 1 milligram of intravenous adrenaline. Following transfer, generalized urticaria erupted across her skin, leading clinicians to suspect perioperative anaphylaxis, a likelihood reinforced by an objective clinical hypersensitivity score of 27 indicating an almost certain immediate reaction.

One week following the initial event, the referring hospital requested commercial laboratory evaluation using the basophil activation test to identify the causative substance among cefazolin, propofol, and levobupivacaine. The commercial facility utilized CD203c as the cellular activation marker, measuring responses after incubation periods of 1 hour and 24 hours across three serial dilutions of 1:312.5, 1:1250, and 1:5000. At the 1-hour incubation mark, basophil activation across all drug concentrations remained below the negative control baseline of 3.8 percent. However, following 24 hours of incubation, the negative control registered a low baseline activation rate of 1.6 percent. At the lowest dilution of 1:312.5, propofol and levobupivacaine demonstrated activation rates of 7.9 percent and 6.1 percent, respectively. The commercial laboratory reported these findings as equivocal positive reactions. Conversely, basophil activation rates for cefazolin remained suppressed at 0.2 percent, well below the negative control baseline, leading clinicians to erroneously dismiss the antimicrobial agent as an innocent bystander while regarding the anesthetic drugs as probable triggers.

Eight weeks after the initial reaction, the patient returned for a second attempt at surgical repair under modified anesthetic planning. Guided by the commercial laboratory report, clinicians avoided both propofol and levobupivacaine, instead inducing general anesthesia with 50 micrograms of fentanyl and 5 percent sevoflurane before inserting a supraglottic airway device. Two minutes after induction, an infusion of 1 gram of cefazolin was initiated. Exactly nine minutes later, the patient suffered recurrent circulatory collapse: systolic blood pressure plummeted into the 50 mmHg range before becoming unmeasurable, accompanied by sinus tachycardia of 100 to 110 beats per minute. Auscultation revealed prominent expiratory wheezing, and peripheral oxygen saturation dropped to 86 percent, though cutaneous manifestations remained absent. Clinicians immediately diagnosed recurrent anaphylaxis and administered an initial intravenous bolus of 50 micrograms of adrenaline, followed by repeated aliquots of 25 to 50 micrograms, delivering a cumulative dose of 500 micrograms over 22 minutes before initiating a continuous adrenaline infusion at 0.1 micrograms per kilogram per minute to stabilize hemodynamics.

Following clinical stabilization and cancellation of the second procedure, an objective evaluation assigned this recurrence a clinical score of 20, confirming that immediate hypersensitivity was very likely. The patient was subsequently referred to the authors’ institution for specialized allergy evaluation and subsequent surgical management under spinal anesthesia. Given that both life-threatening collapses had followed the administration of cefazolin, the antibiotic was strongly suspected as the true culprit. Six weeks after the second anaphylactic episode, comprehensive in vivo skin testing was conducted using cefazolin, lidocaine, and bupivacaine. While skin prick tests for all three pharmaceutical agents yielded negative results, intradermal testing with cefazolin at a concentration of 10 micrograms per milliliter produced a definitive positive reaction. At 15 minutes, the cefazolin intradermal site exhibited an erythematous flare measuring 25 by 22 millimeters and a distinct central wheal measuring 9 by 9 millimeters, providing conclusive in vivo evidence of drug-specific IgE-mediated hypersensitivity.

Nine weeks after the second episode, investigators repeated the in vitro basophil activation test at their own institution using the standardized Allergenicity Kit to systematically evaluate why the initial test had failed. The modified protocol utilized 100 microliters of heparinized whole blood incubated with 20 microliters of a fluorochrome-conjugated antibody cocktail containing CRTH2-FITC, CD203c-PE, and CD3-PC7, along with 20 microliters of each suspected drug, carried out at 37 degrees Celsius for exactly 15 minutes. With a total reaction volume of 140 microliters, the final in vitro drug concentration represented approximately 14.3 percent of the added compound concentration. To assess responsiveness across a broad physiological range, stock preparations of cefazolin at 10 milligrams per milliliter, propofol at 10 milligrams per milliliter, and levobupivacaine at 7.5 milligrams per milliliter were evaluated across five serial dilutions ranging from 1:10 to 1:3000. Applying diagnostic criteria requiring both an absolute activation rate of at least 10 percent and a stimulation index of at least 2 relative to the negative control, cefazolin elicited a clear positive response of 14.3 percent activation at the 1:10 dilution compared to 4.8 percent in the negative control, whereas propofol and levobupivacaine showed no meaningful activation.

The study authors identified two distinct analytical discrepancies responsible for the false-negative cefazolin result in the initial commercial evaluation: inadequate timing after the anaphylactic event and suboptimal in vitro drug concentrations. In standard allergy practice, skin testing is deliberately deferred for 4 to 6 weeks following an anaphylactic event because acute degranulation induces a transient state of cellular anergy or hyporesponsiveness during which mast cells and basophils fail to react normally. Performing the initial basophil activation test merely one week post-event coincided with this refractory recovery window, potentially dampening basophil reactivity. Furthermore, literature evaluating beta-lactam antibiotics indicates that cefazolin possesses distinctive in vitro reaction kinetics requiring relatively high concentrations, generally ranging from 0.6 to 10 milligrams per milliliter, to trigger detectable flow cytometric basophil activation. The commercial assay evaluated serial dilutions of unknown final concentration that were evidently too dilute to cross the threshold of cellular activation, whereas testing at an adequate 1:10 dilution yielded unequivocal positivity.

The investigators also elucidated why the commercial assay produced misleading false-positive interpretations for propofol and levobupivacaine, tracing the error to excessively prolonged incubation and flawed threshold metrics. Standard clinical protocols recommend incubating basophils with allergen solutions for 15 to 30 minutes, whereas the commercial laboratory extended incubation to 24 hours. Prolonged incubation severely compromises cellular viability and perturbs physiological receptor responsiveness, as demonstrated by the positive control’s CD203c expression dropping precipitously from 61.3 percent at 1 hour to 37.9 percent at 24 hours. Furthermore, relying exclusively on a stimulation index greater than 2 without enforcing an absolute activation threshold creates significant diagnostic distortion when the negative control baseline is suppressed. In the commercial test, the 24-hour negative control registered only 1.6 percent activation, allowing minor nonspecific basophil background signals of 6.1 percent and 7.9 percent to appear artificially significant. Enforcing a mandatory absolute threshold, such as 10 percent basophil activation, appropriately reclassifies these equivocal background fluctuations as negative results.

Finally, the authors emphasized that epidemiological realities must actively guide the interpretation of perioperative allergy testing. Registry data and multicenter epidemiological analyses demonstrate that, absent immunological cross-reactivity, true multi-drug perioperative anaphylaxis is exceedingly rare, with common individual triggers occurring in approximately 1 in 20,000 anesthetic exposures. Consequently, finding simultaneous reactivity to chemically unrelated compounds, such as local anesthetics, intravenous hypnotics, and cephalosporins, carries an extremely low pre-test probability and should immediately prompt clinical skepticism. Equipped with validated diagnostic clarity from skin testing and the optimized repeat assay, the patient successfully underwent her scheduled meniscal repair under bupivacaine spinal anesthesia with clindamycin antimicrobial prophylaxis, experiencing an uneventful perioperative course without allergic recurrence. The case conclusively demonstrates that while the basophil activation test represents a valuable, minimally invasive adjunct, establishing harmonized procedural standards for incubation timing, drug concentrations, and diagnostic positivity thresholds remains essential to prevent misclassification and avert recurrent perioperative harm.

Subject of Research: Basophil activation test methodological variability and diagnostic challenges in perioperative anaphylaxis

Article Title: Recurrent anaphylaxis highlighting methodological variability and diagnostic challenges in the basophil activation test: a case report

Article References: Okutomi, K., Sugiyama, Y., Nitta, A., Kimizuka, M., & Yamakage, M. (2026). Recurrent anaphylaxis highlighting methodological variability and diagnostic challenges in the basophil activation test: a case report. JA Clinical Reports, 12(1), Article 39. https://doi.org/10.1186/s40981-026-00872-6

Image Credits: AI Generated

DOI: 10.1186/s40981-026-00872-6

Keywords: basophil activation test, perioperative anaphylaxis, cefazolin hypersensitivity, flow cytometry allergy testing, drug allergy diagnostics, CD203c marker, intradermal skin testing, hypotension in anesthesia, anesthetic drug reactions, propofol allergy evaluation, levobupivacaine hypersensitivity, in vitro allergy testing, stimulation index, basophil hyporesponsiveness, surgical allergy management, clinical allergy scoring

News Source: Ophelia Keating. (November 19, 2026). Methodological Flaws in Basophil Activation Testing Linked to Recurrent Perioperative Anaphylaxis. Scienmag.

Tags: anesthetic drug reactionsbasophil activation testbasophil hyporesponsivenessCD203c markercefazolin hypersensitivityclinical allergy scoringdrug allergy diagnosticsflow cytometry allergy testinghypotension in anesthesiain vitro allergy testingintradermal skin testinglevobupivacaine hypersensitivityperioperative anaphylaxispropofol allergy evaluationstimulation indexsurgical allergy management
Share12Tweet7Share2ShareShareShare1

Related Posts

Multiple Sclerosis Drug Teriflunomide Eases Inflammatory Diseases by Directly Inhibiting NLRP3

Multiple Sclerosis Drug Teriflunomide Eases Inflammatory Diseases by Directly Inhibiting NLRP3

November 19, 2026
Three Modifiable Perioperative Factors Predict Joint Infection Following Knee Arthroplasty

Three Modifiable Perioperative Factors Predict Joint Infection Following Knee Arthroplasty

November 19, 2026

Left Amygdala Activity During Emotional Face Processing Differs in Youth With Autism

November 19, 2026

Study in Saudi Arabia Reveals Distinct Gender Differences in Mental Health Stigma

November 19, 2026

POPULAR NEWS

  • First-Principles Calculations Reveal High Thermoelectric Efficiency and Half-Metallicity in Co2VPb Alloy

    First-Principles Calculations Reveal High Thermoelectric Efficiency and Half-Metallicity in Co2VPb Alloy

    29 shares
    Share 12 Tweet 7
  • Mobile Bird Hosts Enable Regional Gene Flow in Crater Lake Parasites

    29 shares
    Share 12 Tweet 7
  • Ultrasound Shows Low Diagnostic Accuracy for Sexing Immature Agile Frogs

    29 shares
    Share 12 Tweet 7
  • Lithuanian Forest Foragers Link Solitary Mushroom Gathering to Cross-Border Trade

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Element AVITI Demonstrates Higher Quality Scores Than Illumina NovaSeq Across Diverse Applications

Targeting PANoptosis Regulators Reduces Tissue Injury in Preclinical Ischemia Models

Multiple Sclerosis Drug Teriflunomide Eases Inflammatory Diseases by Directly Inhibiting NLRP3

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.